Medidata and the National Cancer Institute Extend 15-Year Partnership for an Additional Five Years
Medidata has announced an extension of its 15-year relationship with the National Cancer Institute (NCI), part of the National Institutes of Health. This renewed commitment, spanning an additional five years, consolidates their joint efforts and underscores their dedication to advancing cancer research.
Since the inception of their partnership in 2008, Medidata and the NCI have collaborated across thousands of clinical trials with the joint mission of pioneering the development of promising treatments of cancer.
“Medidata’s long-standing partnership with the NCI represents our unwavering commitment to supporting critical oncology research,” says Joseph Schmidt, executive vice president, customer success, services, and support, Medidata in a press release. “It is gratifying that 90% of all oncology approvals last year in the US were developed using Medidata software, and we hope to make an even bigger impact alongside the NCI over the next few years in the fight against cancer.”
By standardizing processes and enhancing data collection, the Medidata platform supports accelerated study timelines with the goal of bringing innovative and transformative therapies to patients sooner.
The company’s combination of expertise and clinical trial technologies extends its support to public sector research organizations, encompassing over 3,000 academic clinical trials, 223,000 sites, and benefiting 948,000 patients.
Reference
Medidata and the National Cancer Institute Extend 15-Year Partnership for an Additional Five Years. (2023, October 4). Business Wire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.
